Can Supernus Pharmaceuticals (SUPN) Stock Reach $62?

Key Takeaways

• The central target of $62 is the arithmetic mean of six verified analyst price targets, rounded from roughly $62.17, with individual targets ranging from $55 to $67.
• The latest verified close is about $41.92, meaning the target implies an upside of roughly 48% — a very large move from current levels.
• Analyst views are mostly bullish but not uniform: five firms carry Buy-equivalent ratings, while Stifel holds a Neutral/Hold rating at $55.
• Strongest supports include record quarterly revenue, raised 2026 guidance, and the pending transformational merger with Indivior Pharmaceuticals.
• Biggest risks are integration execution, a GAAP net loss for the first nine months, and targets that may not fully reflect the post-merger combined company.
• Readers can find more detail on the ticker's Major News, Today's Price Move, Forecast, and Earnings on additional pages.
• Explore Trending AI Robots to see AI-driven trading strategies in action.

Analyst Price Targets and Consensus View

Supernus Pharmaceuticals, Inc. (SUPN) is a biopharmaceutical company focused on central nervous system (CNS) diseases, including ADHD, Parkinson's disease, postpartum depression, epilepsy, and migraine. It is a stock, not an exchange-traded fund.

Reviewing the most recent published targets from covering firms yields six distinct figures. Bank of America Securities (Chi Meng Fong) holds a Buy with a target of $55, lowered from $60 in mid-October; TD Cowen (Stacy Ku) maintains a Buy at $65; Piper Sandler reiterates a Buy at $66; Jefferies maintains a Buy at $65; Cantor Fitzgerald (Kristen Kluska) has a Buy at $67; and Stifel Nicolaus (Annabel Samimy) carries a Hold at $55. The resulting range is $55 to $67, and the arithmetic mean is about $62.17, rounded to $62.

Views differ mainly on the launch trajectory of Onapgo and on how much credit to give the pending Indivior combination. BofA's $55 and Stifel's $55 reflect a more cautious stance on near-term launch economics, while the $65-plus targets lean on the company's growth-product momentum and merger-driven scale. Notably, several targets predate the merger's final stages and may not yet reflect the combined entity's outlook.

Current Market Position and Path Toward the Target

With the stock near $41.92, reaching $62 requires an increase of roughly 48% — a very large move. The shares sit well below their 52-week high of about $59.68 but above the 52-week low near $37.54, and they have lost roughly 17% year-to-date despite a stronger broad market.

The path toward the target would likely depend on the combined company realizing its forecast cost synergies, sustaining double-digit prescription growth in products such as Qelbree and Zurzuvae, and converting improved operating leverage into higher earnings. In the third quarter of 2026, Supernus reported record total revenue of $226.8 million, up 18% year over year, and raised full-year standalone revenue guidance to a range of $875 million to $900 million, with non-GAAP operating earnings of $160 million to $180 million.

What Could Support a Move Toward the Target

• Growth-product momentum: Combined revenue from Qelbree, Zurzuvae, Onapgo, and Gocovri rose about 43% year over year in the third quarter.
• Onapgo exclusivity: The FDA granted seven years of orphan drug exclusivity for Onapgo in advanced Parkinson's disease, a meaningful competitive moat.
• Zurzuvae collaboration: Supernus reported $42 million in collaboration revenue for the quarter, with U.S. sales reported by Biogen up about 53%.
• Indivior merger: Shareholders approved the deal, with management citing roughly $125 million in expected annual cost synergies and a combined portfolio spanning psychiatry, neurology, and addiction.

What Could Prevent the Target From Being Reached

• Integration risk: Combining with Indivior is complex, and cost-synergy targets are not guaranteed to be realized on schedule.
• GAAP profitability: The company posted a GAAP net loss of about $39.8 million for the first nine months of 2026, though it was GAAP-profitable in the third quarter.
• Launch execution: Onapgo enrollment forms have hovered around 400 per quarter, suggesting new patient starts could plateau without further acceleration.
• Valuation and sentiment: A 48% gain implies the market must re-rate the stock meaningfully, which could stall if growth disappoints or if analyst targets are revised lower post-merger.

Technical Levels and Market Structure

The stock's 52-week range of roughly $37.54 to $59.68 provides a useful reference. A move toward $62 would require the shares to clear prior resistance near the $59.68 high and break into new 52-week territory, with the psychological $60 level as an intermediate marker. On the downside, the area near $40 and the 52-week low near $37.54 are durable reference levels that would need to hold for the target to remain in view.

Time Horizon and What Investors Should Monitor

Analyst price targets typically reflect a research horizon of around 12 months, though the actual horizon varies by firm and several current targets predate the merger's closing. Investors should watch the completion of the Indivior transaction, the first combined-company 2027 guidance expected in February, Onapgo prescription trends, Zurzuvae sales growth reported by Biogen, and any post-merger analyst target revisions. Pipeline data for SPN-820 and SPN-817 are further out and less likely to move the near-term target debate.

AI Daily Buy/Sell Signals

Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. Traders can use these signals to discover opportunities, monitor existing positions, and spot shifting trends more efficiently than manual screening alone. For those tracking a volatile name such as SUPN, automated signal monitoring can help surface changes in momentum before they are widely reflected in analyst commentary.

Final Assessment

The $62 central target reflects the arithmetic mean of six analyst targets spanning $55 to $67, and it sits roughly 48% above the recent price near $41.92. Achieving it would require the combined Supernus-Indivior company to deliver on cost synergies, sustain growth-product momentum, and convince the market to assign a higher multiple. The principal obstacles are integration execution, persistent GAAP losses on a year-to-date basis, and the possibility that post-merger target revisions moderate the current range. Analysts broadly lean bullish, but the $55-to-$67 spread shows genuine disagreement about the pace of the launch and the merger's value. No outcome is guaranteed; the trajectory will hinge on combined-company guidance and near-term commercial execution.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations